Industry News Roundup
This article was originally published in The Tan Sheet
Executive Summary
DASCA facilitates DEA’s steroid scheduling; U.K. ad authority sneezes at hay fever claim; Nutroganics acquires Wholesoy; hemp migraine relief distribution lit; Clif’s cashew recipe trips some customers; ONHA sponsors GrassrootsHealth nutrient research; baby wipe recall reaches 4M units; and Nasdaq reprieve for Rock Creek.
You may also be interested in...
Between A Rock Creek And A Hard Place: Firm Stops Supplement Sales, Weathers Litigation
Rock Creek Pharmaceuticals faces investor and consumer class-action complaints on top of ending sales of its nutritionals following an FDA warning. Moreover, the company name is known more in connection with federal officials’ investigation of the former governor of Virginia than for its products.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.